These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 30768163)

  • 1. Inflammation status in HIV-positive individuals correlates with changes in bone tissue quality after initiation of ART.
    Lerma-Chippirraz E; Pineda-Moncusí M; González-Mena A; Soldado-Folgado J; Knobel H; Trenchs-Rodríguez M; Díez-Pérez A; Brown TT; García-Giralt N; Güerri-Fernández R
    J Antimicrob Chemother; 2019 May; 74(5):1381-1388. PubMed ID: 30768163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in bone quality after switching from a TDF to a TAF based ART: A pilot randomized study.
    Soldado-Folgado J; Rins-Lozano O; Arrieta-Aldea I; Gonzále-Mena A; Cañas-Ruano E; Knobel H; Garcia-Giralt N; Güerri-Fernández R
    Front Endocrinol (Lausanne); 2023; 14():1076739. PubMed ID: 37051195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone density, microarchitecture, and tissue quality after 1 year of treatment with tenofovir disoproxil fumarate.
    Güerri-Fernández R; Lerma-Chippirraz E; Fernandez Marron A; García-Giralt N; Villar-García J; Soldado-Folgado J; González-Mena A; Trenchs-Rodríguez M; Guelar A; Díez-Pérez A; Brown TT; Knobel H
    AIDS; 2018 Apr; 32(7):913-920. PubMed ID: 29424785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone Density, Microarchitecture, and Tissue Quality After Long-Term Treatment With Tenofovir/Emtricitabine or Abacavir/Lamivudine.
    Güerri-Fernández R; Molina-Morant D; Villar-García J; Herrera S; González-Mena A; Guelar A; Trenchs-Rodríguez M; Díez-Pérez A; Knobel H
    J Acquir Immune Defic Syndr; 2017 Jul; 75(3):322-327. PubMed ID: 28418990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone density, microarchitecture and tissue quality after 1 year of treatment with dolutegravir/abacavir/lamivudine.
    Soldado-Folgado J; Lerma-Chippirraz E; Arrieta-Aldea I; Bujosa D; García-Giralt N; Pineda-Moncusi M; Trenchs-Rodríguez M; Villar-García J; González-Mena A; Díez-Pérez A; Brown TT; Knobel H; Güerri-Fernández R
    J Antimicrob Chemother; 2020 Oct; 75(10):2998-3003. PubMed ID: 32710105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.
    Cotter AG; Vrouenraets SM; Brady JJ; Wit FW; Fux CA; Furrer H; Brinkman K; Sabin CA; Reiss P; Mallon PW;
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1659-66. PubMed ID: 23436922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
    Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
    J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Human Immunodeficiency Virus Infection With Tenofovir Disoproxil Fumarate-Containing Antiretrovirals Maintains Low Bone Formation Rate, But Increases Osteoid Volume on Bone Histomorphometry.
    Ramalho J; Martins CSW; Galvão J; Furukawa LN; Domingues WV; Oliveira IB; Dos Reis LM; Pereira RM; Nickolas TL; Yin MT; Eira M; Jorgetti V; Moyses RM
    J Bone Miner Res; 2019 Sep; 34(9):1574-1584. PubMed ID: 31269294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
    Gafni RI; Hazra R; Reynolds JC; Maldarelli F; Tullio AN; DeCarlo E; Worrell CJ; Flaherty JF; Yale K; Kearney BP; Zeichner SL
    Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of tenofovir disoproxil fumarate on bone metabolism and bone mass among perinatally HIV-infected Asian adolescents.
    Sudjaritruk T; Bunupuradah T; Aurpibul L; Kosalaraksa P; Kurniati N; Sophonphan J; Ananworanich J; Puthanakit T;
    Antivir Ther; 2017; 22(6):471-479. PubMed ID: 27786155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.
    McComsey GA; Lupo S; Parks D; Poggio MC; De Wet J; Kahl LP; Angelis K; Wynne B; Vandermeulen K; Gartland M; Cupo M; Aboud M;
    AIDS; 2018 Feb; 32(4):477-485. PubMed ID: 29239893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels.
    Negredo E; Diez-Pérez A; Bonjoch A; Domingo P; Pérez-Álvarez N; Gutierrez M; Mateo G; Puig J; Echeverría P; Escrig R; Clotet B
    J Antimicrob Chemother; 2015 Jul; 70(7):2104-7. PubMed ID: 25769303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged Effect of Zoledronic Acid on Bone Mineral Density and Turnover in HIV-Infected Adults on Tenofovir: A Randomized, Open-Label Study.
    Carr A; Kerr SJ; Richardson R; Ebeling P; Pocock N; Rojas J; Martinez E; Hoy J;
    J Bone Miner Res; 2019 Dec; 34(12):2192-2197. PubMed ID: 31361922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy.
    Kim-Chang JJ; Wilson L; Chan C; Fischer B; Venturi G; Goodenow MM; Aldrovandi G; Weber TJ; Sleasman JW;
    AIDS Res Hum Retroviruses; 2019 Aug; 35(8):746-754. PubMed ID: 31115244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis.
    Mirembe BG; Kelly CW; Mgodi N; Greenspan S; Dai JY; Mayo A; Piper J; Akello CA; Kiweewa FM; Magure T; Nakabiito C; Marrazzo JM; Chirenje ZM; Riddler SA;
    J Acquir Immune Defic Syndr; 2016 Mar; 71(3):287-94. PubMed ID: 26866954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study.
    Han WM; Wattanachanya L; Apornpong T; Jantrapakde J; Avihingsanon A; Kerr SJ; Teeratakulpisarn N; Jadwattanakul T; Chaiwatanarat T; Buranasupkajorn P; Ramautarsing R; Phanuphak N; Sunthornyothin S; Ruxrungtham K; Phanuphak P;
    PLoS One; 2020; 15(3):e0230368. PubMed ID: 32210458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral-naïve HIV-infected patients had lower bone formation markers than HIV-uninfected adults.
    Wattanachanya L; Jantrapakde J; Avihingsanon A; Ramautarsing R; Kerr S; Trachunthong D; Pussadee K; Teeratakulpisarn N; Jadwattanakul T; Chaiwatanarat T; Buranasupkajorn P; Phanuphak N; Sunthornyothin S; Phanuphak P;
    AIDS Care; 2020 Aug; 32(8):984-993. PubMed ID: 31137948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.
    Hoy JF; Richardson R; Ebeling PR; Rojas J; Pocock N; Kerr SJ; Martinez E; Carr A;
    AIDS; 2018 Sep; 32(14):1967-1975. PubMed ID: 29927785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenofovir Disoproxil Fumarate Use during Pregnancy and Infant Bone Health: the Tenofovir in Pregnancy Pilot Study.
    Kourtis AP; Wiener J; Wang L; Fan B; Shepherd JA; Chen L; Liu W; Shepard C; Wang L; Wang A; Bulterys M
    Pediatr Infect Dis J; 2018 Nov; 37(11):e264-e268. PubMed ID: 30067600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients.
    Casado JL; Santiuste C; Vazquez M; Bañón S; Rosillo M; Gomez A; Perez-Elías MJ; Caballero C; Rey JM; Moreno S
    AIDS; 2016 Jun; 30(9):1423-31. PubMed ID: 26919733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.